GROWTH HORMONE AXIS / FAQ
Questions From the Trial Record
Direct, citation-anchored answers to the questions readers most often bring to these three GH-axis research peptides.
What is CJC-1295?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It is not an FDA-approved drug — it is sold as a research chemical. Four amino-acid substitutions make it more stable than native GHRH, and a variant called DAC adds an albumin-binding arm that extends its action from minutes to days [4]. It works by binding the GHRH receptor on the pituitary gland, stimulating growth hormone (GH) release.
What does CJC-1295 do?
In published pharmacology studies, single doses of CJC-1295 raised mean plasma GH 2- to 10-fold for six or more days, and IGF-1 1.5- to 3-fold for 9 to 11 days, with an estimated half-life of 5.8 to 8.1 days [4]. A companion study found the normal pulsatile pattern of GH secretion persisted under continuous CJC-1295 stimulation — it amplifies the existing rhythm rather than replacing it with a flat, constant signal [5].
Is CJC-1295 safe?
CJC-1295 has not cleared a large or long-term human safety trial. Its published human data come from small, short pharmacology studies in a few dozen healthy adults. Sustained GH and IGF-1 elevation raises a mechanism-based cancer concern, since IGF-1 is a growth factor associated in epidemiologic data with certain cancers — an association, not proof of cause. It can also affect blood-sugar handling [12] and cause fluid retention. This is not a settled safety profile; it is an open question with limited evidence in either direction.
How much CJC-1295 should I take?
This site does not recommend a dose for CJC-1295, for any use. In the published pharmacology trials, researchers used single subcutaneous doses of 30, 60, or 90 micrograms per kilogram of body weight to study its effect on GH and IGF-1 [4][5]. Those figures describe a research protocol, not a suggested dose for any individual. CJC-1295 is not approved for human use, and there is no clinically established dosing standard for it.
What is CJC-1295 / Ipamorelin good for?
In research-use communities, this combination is most often discussed in the context of sleep quality, training recovery, and gradual body-composition change. None of that is established in a controlled trial of the combination itself — no such trial exists. What is established is the mechanism: CJC-1295 supplies a long-acting GHRH signal, and ipamorelin adds a second, independent GH-release pathway through the ghrelin receptor, with cell-based work showing the two pathways interact rather than simply stacking [9].
What are the bad side effects of CJC-1295 and Ipamorelin?
Community reports most often describe injection-site redness or swelling, transient water retention, a brief facial flush after dosing, and occasional tingling in the hands — all anecdotal, not clinical evidence. From the cited literature, the class-level concerns are reduced insulin sensitivity and higher blood glucose [7], and a mechanism-based cancer concern tied to sustained IGF-1 elevation [7]. Because the fixed combination has never been trialed, its full adverse-effect profile is simply not documented anywhere.
How long do CJC-1295 and Ipamorelin take to work?
There is no trial of the combination to answer this directly. For CJC-1295 alone, single-dose studies showed GH elevation within hours and IGF-1 elevation lasting 9 to 28 days depending on dose and DAC status [4]. Ipamorelin's own GH pulse is short — on the order of hours, based on its selective, single-receptor action. Community reports of subjective effects like sleep quality commonly describe a one-to-two-week window, but that is a self-reported pattern, not a measured pharmacokinetic result.
How many mg of CJC-1295 and Ipamorelin should I take?
This site does not provide a dose for either compound. Published pharmacology studies of CJC-1295 alone used single doses in the 30-90 microgram-per-kilogram range [4][5]. No published trial has established a dose for the fixed CJC-1295 + ipamorelin combination, because no such trial exists. Treating an online 'protocol' as an established clinical dose means relying on unverified, non-trial information.
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analog of human growth-hormone-releasing hormone (GHRH), modified to resist enzymatic breakdown. It is FDA-approved, but for one specific use: reducing excess visceral fat in HIV-infected adults with a defined fat-redistribution condition [14]. It works by binding the GHRH receptor on the pituitary gland to stimulate growth hormone release.
What does tesamorelin do?
In its pivotal 26-week trial, tesamorelin reduced visceral adipose tissue by 15.2% versus a 5.0% increase with placebo, cut triglycerides by 50 mg/dL, and raised IGF-1 by 81.0% [14]. A 2026 meta-analysis across five trials found consistent reductions in visceral fat, hepatic fat, and increases in lean mass, with no serious adverse events [6]. All of these results come from HIV-positive adults with lipodystrophy — the approved population, not the general public.
How does tesamorelin work?
Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, triggering the same cAMP signaling cascade used by other GHRH analogs on this desk. That stimulates pulsatile release of growth hormone, which raises IGF-1 in the liver. GH and IGF-1 together promote lipolysis, with a documented preference for visceral fat over other fat depots [11]. Because tesamorelin amplifies the body's own GH rhythm rather than supplying GH directly, its metabolic profile differs from giving growth hormone itself.
Will tesamorelin help me lose belly fat?
This site does not make individual predictions. What the trials show: in HIV-positive adults with lipodystrophy, tesamorelin reduced visceral fat by 15.2% to 18% across studies of 26 to 52 weeks, with fat returning once dosing stopped [13][14]. Those results are specific to that population and that condition. There is no equivalent trial evidence for tesamorelin's effect on general abdominal fat in people without HIV-associated lipodystrophy.